Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
1. Cingulate submitted NDA for CTx-1301 to the FDA on July 31, 2025. 2. FDA decision on NDA acceptance expected in Q4 2025. 3. CTx-1301 aims to improve ADHD treatment with whole-day efficacy. 4. Cingulate plans to raise additional capital for commercialization efforts. 5. Company reported a net loss of $4.8 million for Q2 2025.